Developing science,
delivering therapies

4d

Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach
developing-science

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do
delivering-therapies

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more

News

4D pharma announces opening of a study investigating MRx0518 in combination with radiotherapy in patients with resectable pancreatic cancer
4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live Biotherapeutics, today announced preliminary safety and clinical observations from an ongoing Phase I/II clinical trial, in collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate its lead oncology candidate, MRx0518, in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in patients with advanced malignancies who have previously responded and whose disease has then progressed on PD-1/PD-L1 inhibitors. These are the first observations from an oncology study in man involving a Live Biotherapeutic Product.
4D pharma plc today announces that the Company has entered into a research collaboration and option to license agreement with MSD to discover and develop Live Biotherapeutics for vaccines

BACK TO TOP